Welcome to our dedicated page for Liquidia news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia stock.
Liquidia Corporation develops and commercializes therapies for respiratory and vascular diseases, with a focus on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its updates center on YUTREPIA® (treprostinil) inhalation powder, the company’s PRINT® Technology-enabled approved therapy, along with L606, an investigational extended-release treprostinil formulation administered with a nebulizer, and generic Treprostinil Injection for PAH.
Recurring news includes financial results, YUTREPIA commercial uptake, clinical data presentations, pipeline studies, corporate presentations and investor conference participation. Company updates also discuss treprostinil delivery, PAH and PH-ILD treatment settings, cash generation and profitability as product sales become a larger part of Liquidia’s operating profile.
Liquidia Technologies (NASDAQ: LQDA) has successfully closed a public offering of 9,375,000 shares at $8.00 each, generating total gross proceeds of $75 million. This offering follows a previously filed registration statement with the SEC. The underwriters have a 30-day option to purchase an additional 1,406,250 shares. Jefferies acted as the sole book-running manager with Needham & Company and Wedbush PacGrow as co-managers. The securities will not be offered where prohibited by state laws.
Liquidia Technologies (NASDAQ: LQDA) will host a webcast and conference call on June 30, 2020, at 8:00 a.m. ET to discuss updates regarding the proposed acquisition of RareGen and an ongoing common stock offering. Investors can join via domestic dial-in (1-877-707-8711) or international dial-in (1-857-270-6219) using passcode 4836889. Liquidia focuses on innovative drug delivery via PRINT® technology, targeting conditions like pulmonary arterial hypertension (LIQ861) and post-operative pain (LIQ865). For more details, visit Liquidia's website.
Liquidia Technologies, Inc. (NASDAQ: LQDA) announced a public offering of 9,375,000 shares of common stock at $8.00 each, yielding gross proceeds of $75 million. This offering is solely by Liquidia, with a 30-day option for underwriters to purchase an additional 1,406,250 shares. The transaction is expected to close on July 2, 2020. Jefferies serves as the sole book-running manager. The offering is conducted under a shelf registration statement declared effective by the SEC in September 2019, and related documents can be accessed via the SEC website.
Liquidia Technologies (NASDAQ: LQDA) has announced its acquisition of RareGen, LLC, enhancing its capabilities in pulmonary arterial hypertension (PAH) treatment. The all-stock merger, expected to close in Q4 2020, will create Liquidia Corporation and allow it to promote RareGen's generic treprostinil. This strategic move is aimed at improving the company's commercial readiness for LIQ861, an inhaled treatment for PAH. The merger is set to bolster Liquidia's market presence, integrating RareGen's sales force and expertise in rare diseases.
Liquidia Technologies (LQDA) has announced a patent infringement lawsuit filed by United Therapeutics Corporation against it, relating to its New Drug Application (NDA) for LIQ861, a dry powder inhalation of treprostinil for pulmonary arterial hypertension (PAH). The case, filed under the Hatch-Waxman Act, could delay FDA approval of LIQ861 by up to 30 months. Liquidia asserts that the patents are either invalid or not infringed and intends to defend against the suit vigorously. The company has previously filed petitions for inter partes review of the patents, with a decision expected by Q3 2020.
Liquidia Technologies (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company, announced that CEO Neal Fowler will present an overview at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 10:30 AM ET. The event will be accessible via a live audio webcast, available on the company’s website and archived for 90 days. Liquidia focuses on developing novel products using its proprietary PRINT® technology, aiming to enhance therapy safety and efficacy. Notable product candidates include LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain.
Liquidia Technologies (LQDA) announced the appointment of Dr. Tushar Shah as Chief Medical Officer. Dr. Shah brings 27 years of experience in pharmaceutical research, overseeing clinical development activities. His previous roles include Head of Global Specialty Clinical Development at Teva Pharmaceuticals. This leadership change is expected to enhance Liquidia's capabilities, particularly as it advances LIQ861 (pending NDA review) and LIQ865 (currently in clinical development), utilizing Liquidia's proprietary PRINT technology.
Liquidia Technologies, Inc. (LQDA) will announce its first quarter 2020 financial results on May 11, 2020, at 4:30 p.m. ET. The company plans to host a webcast and conference call to discuss these results and provide a corporate update.
Liquidia is focused on developing novel biopharmaceutical products using its proprietary PRINT® technology, with two primary candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain treatment.
Summary not available.